Arquivamento - Art. 36 §1° da LPI
#11.2
07/23/2024
RPI 2794
Back to search
Official data from INPI
ANTAGONISTAS DE RECEPTOR DE FATOR DE LIBERAÇÃO DE CORTICOTROPINA
ArquivadaInvention PatentPCT · US2018046707
Application data
Number
112020002966Type
Invention Patent
Filing
08/14/2018
Publication
08/11/2020
PCT
US2018046707 Progress at the INPI
- Filing08/14/18
- Publication08/11/20
- Abandoned
- Allowance
- Grant
- In force
The application was abandoned: the INPI technical office action was not answered in time (art. 36 of the Brazilian IP Act). The technology is in the public domain in Brazil.
Talk to a specialistLatest action published by the INPI: 07/23/2024. We update with every new RPI gazette, published weekly.
Applicants and inventors
Applicants
SPRUCE BIOSCIENCES, INC.
US
Inventors
A. H. (pessoa física)
US
H. G. (pessoa física)
US
S. K. (pessoa física)
US
Technical data
IPC Classification
Priority claims
US
62/545,393 · 08/14/2017
Abstract
A presente invenção fornece composições farmacêuticas inovadoras que compreendem 3-(4-cloro-2-(morfolin-4-il)tiazol-5-il)-7-(1-etilpropil)-2,5-dimetilpirazolo(1,5-a)pirimidina e métodos de utilização dos mesmos para o tratamento da hiperplasia adrenal congênita (HAC).
Prosecution history
Publications in the Brazilian Industrial Property Gazette (RPI).
Parecer de pré-exame
#6.23
02/15/2024
RPI 2771
Alteração de sede deferida
#25.7
09/05/2023
RPI 2748
Adição na publicação
#15.35
11/03/2021
RPI 2652
Notificação de entrada na fase nacional - PCT
#1.3
08/11/2020
RPI 2588
Alteração de dados cadastrais
#1.1
02/27/2020
RPI 2564
Related
From the same holder
Same category
Patent monitoring
Track this patent in real time.
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.